Longitudinal association between medication adherence and lung health in people with cystic fibrosis

Journal of Cystic Fibrosis

Volumn 10, Issue 4, 2011, Pages 258-264

  Eakin, Michelle N ^a   Bilderback, Andrew ^a   Boyle, Michael P ^a   Mogayzel, Peter J ^a   Riekert, Kristin A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adherence; Cystic fibrosis; Health outcomes; Pulmonary exacerbation; Treatment

Indexed keywords

ANTIBIOTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CHILD; CYSTIC FIBROSIS; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FIBROSIS; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; SCHOOL CHILD;

ADOLESCENT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHILD; CYSTIC FIBROSIS; DEOXYRIBONUCLEASE I; DRUG PRESCRIPTIONS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INFUSIONS, INTRAVENOUS; LONGITUDINAL STUDIES; MALE; MEDICATION ADHERENCE; OUTCOME ASSESSMENT (HEALTH CARE); PHARMACY; RETROSPECTIVE STUDIES; TOBRAMYCIN; YOUNG ADULT;

EID: 79958294193     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2011.03.005     Document Type: Article

References (43)

1. Flume P.A., O'Sullivan B.P., Robinson K.A., Goss C.H., Mogayzel P.J., Willey-Courand D.B., et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007, 176(10):957-969.
2. Burrows J.A., Bunting J.P., Masel P.J., Bell S.C. Nebulised dornase alpha: adherence in adults with cystic fibrosis. J Cyst Fibros 2002, 1(4):255-259.
3. Elkins M.R., Robinson M., Rose B.R., Harbour C., Moriarty C.P., Marks G.B., et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006, 354(3):229-240.
4. Modi A.C., Lim C.S., Yu N., Geller D., Wagner M.H., Quittner A.L. A multi-method assessment of treatment adherence for children with cystic fibrosis. J Cyst Fibros 2006, 5(3):177-185.
5. Quinn J., Latchford G., Duff A., Conner M., Pollard K., Morrison L., et al. Measuring, predicting and improving adherence to inhalation in patients with CF: a randomised controlled study of motivational interviewing. Pediatr Pulmonol 2004, S27:360.
6. Quittner A.L., Drotar D., Ievers-Landis C. Improving adherence in adolescents with cystic fibrosis: comparisons of family therapy and psychoeducation. Paper Presented at the Society of Pediatric Psychology National Conference on Child Health Psychology, Charleston SC 2004.
7. Zindani G.N., Streetman D.D., Streetman D.S., Nasr S.Z. Adherence to treatment in children and adolescent patients with cystic fibrosis. J Adolesc Health 2006, 38(1):13-17.
8. McNally K.A., Rohan J., Schluchter M., Riekert K.A., Vavrek P., Schmidt A., et al. Adherence to combined montelukast and fluticasone treatment in economically disadvantaged African American youth with asthma. J Asthma 2009, 46(9):921-927.
9. McQuaid E.L., Kopel S.J., Klein R.B., Fritz G.K. Medication adherence in pediatric asthma: reasoning, responsibility, and behavior. J Pediatr Psychol 2003, 28(5):323-333.
10. Bender B., Zhang L. Negative affect, medication adherence, and asthma control in children. J Allergy Clin Immunol 2008, 122(3):490-495.
11. Burrows J.A., Bunting J.P., Masel P.J., Bell S.C. Nebulised dornase alpha: adherence in adults with cystic fibrosis. J Cyst Fibros 2002, 1:255-259.
12. Fong S.L., Dales R.E., Tierney M.G. Compliance among adults with cystic fibrosis. DICP 1990, 24(7-8):689-692.
13. Eakin M.N., Bilderback A.L., Boyle M.P., Mogayzel P.J., Riekert K.A. The association between medication adherence and lung function among patients with Cystic Fibrosis. Am J Respir Crit Care Med 2009, 179:A1088.
14. Riekert K.A., Mogayzel P.J., Bilderback A., Hale W., Boyle M.P. Medication adherence among children, adolescents and adults with CF. Pediatr Pulmonol Suppl 2007, 30:405.
15. Cystic Fibrosis Foundation Cystic Fibrosis Foundation Patient Registry. 2007 Annual Data Report 2008, Cystic Fibrosis Foundation, Bethesda, MD.
16. Fuchs H.J., Borowitz D.S., Christiansen D.H., Morris E.M., Nash M.L., Ramsey B.W., et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The pulmozyme study group. N Engl J Med 1994, 331(10):637-642.
17. Liou T.G., Adler F.R., FitzSimmons S.C., Cahill B.C., Hibbs J.R., Marshall B.C. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001, 153(4):345-352.
18. Dasenbrook E.C., Checkley W., Merlo C.A., Konstan M.W., Lechtzin N., Boyle M.P. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA 2010, 303(23):2386-2392.
19. Ortiz J.R., Neuzil K.M., Victor J.C., Wald A., Aitken M.L., Goss C.H. Influenza-associated cystic fibrosis pulmonary exacerbations. Chest 2010, 137(4):852-860.
20. Steiner J.F., Prochazka A.V. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997, 50(1):105-116.
21. Hankinson J.L., Odencrantz J.R., Fedan K.B. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999, 159(1):179-187.
22. Kuczmarski R.J., Ogden C.L., Guo S.S., Grummer-Strawn L.M., Flegal K.M., Mei Z., et al. 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 2002, 246:1-190.
23. Konstan M.W., Wagener J.S., Yegin A., Millar S.J., Pasta D.J., VanDevanter D.R. Design and powering of cystic fibrosis clinical trials using rate of FEV(1) decline as an efficacy endpoint. J Cyst Fibros 2010, 9(5):332-338.
24. Davis P.B., Byard P.J., Konstan M.W. Identifying treatments that halt progression of pulmonary disease in cystic fibrosis. Pediatr Res 1997, 41(2):161-165.
25. Freemantle N., Calvert M., Wood J., Eastaugh J., Griffin C. Composite outcomes in randomized trials: greater precision but with greater uncertainty?. JAMA 2003, 289(19):2554-2559.
26. Quan J.M., Tiddens H.A., Sy J.P., McKenzie S.G., Montgomery M.D., Robinson P.J., et al. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 2001, 139(6):813-820.
27. Cobos N., Danes I., Gartner S., Gonzalez M., Linan S., Arnau J.M. DNase use in the daily care of cystic fibrosis: who benefits from it and to what extent? Results of a cohort study of 199 patients in 13 centres. DNase National Study Group. Eur J Pediatr 2000, 159(3):176-181.
28. McPhail G.L., Acton J.D., Fenchel M.C., Amin R.S., Seid M. Improvements in lung function outcomes in children with cystic fibrosis are associated with better nutrition, fewer chronic pseudomonas aeruginosa infections, and dornase alfa use. J Pediatr 2008, 153(6):752-757.
29. Ramsey B.W., Pepe M.S., Quan J.M., Otto K.L., Montgomery A.B., Williams-Warren J., et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999, 340(1):23-30.
30. McCoy K., Hamilton S., Johnson C. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group. Chest 1996, 110(4):889-895.
31. Saiman L., Mayer-Hamblett N., Campbell P., Marshall B.C. Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. Am J Respir Crit Care Med 2005, 172(8):1008-1012.
32. Clement A., Tamalet A., Leroux E., Ravilly S., Fauroux B., Jais J.P. Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax 2006, 61(10):895-902.
33. Miller L.G., Liu H., Hays R.D., Golin C.E., Beck C.K., Asch S.M., et al. How well do clinicians estimate patients' adherence to combination antiretroviral therapy?. J Gen Intern Med 2002, 17(1):1-11.
34. Bieszk N., Patel R., Heaberlin A., Wlasuk K., Zarowitz B. Detection of medication nonadherence through review of pharmacy claims data. Am J Health Syst Pharm 2003, 60(4):360-366.
35. Finney J.W., Hook R.J., Friman P.C., Rapoff M.A., Christophersen E.R. The overestimation of adherence to pediatric medical regimens. Child Health Care 1993, 22(4):297-304.
36. Daniels T., Goodacre L., Sutton C., Pollard K., Conway S., Peckham D. Accurate assessment of adherence: self and clinician report versus electronic monitoring of nebulizers. Chest 2011, published head of print.
37. Patel U.D., Davis M.M. Physicians' attitudes and practices regarding adherence to medical regimens by patients with chronic illness. Clin Pediatr Phila 2006, 45(5):439-445.
38. George M., Rand-Giovannetti D., Eakin M.N., Borrelli B., Zettler M., Riekert K.A. Perceptions of barriers and facilitators: self-management decisions by older adolescents and adults with CF. J Cyst Fibros 2010, 9(6):425-432.
39. Kripalani S., Yao X., Haynes R.B. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med 2007, 167(6):540-550.
40. Quittner A., Drotar D., Ievers-Landis C., Slocum N. Adherence to medical treatments in adolescents with cystic fibrosis: the development and evaluation of family-based interventions. Promoting Adherence to Medical Treatment in Chronic Childhood Illness; Concepts, Methods and Intervention 2000, 383-407. Lawrence Erlbaum Associates, New Jersey. D. Drotar (Ed.).
41. Choo P.W., Rand C.S., Inui T.S., Lee M.L., Cain E., Cordeiro-Breault M., et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care 1999, 37(9):846-857.
42. Riekert K.A., Rand C.S. Electronic monitoring of adherence: when is high-tech best?. J Clin Psych Med Settings 2002, 9:25-34.
43. Schechter M.S., McColley S.A., Silva S., Haselkorn T., Konstan M.W., Wagener J.S. Association of socioeconomic status with the use of chronic therapies and healthcare utilization in children with cystic fibrosis. J Pediatr 2009, 155(5):634-639.